Table 3.
Effect of MRA Treatment on Clinical Outcomes Overall, and in Each SBP Category
| Outcome | Number of Events (%) |
Adjusted HR (95% CI), p Value | p Value for Interaction∗ | ||
|---|---|---|---|---|---|
| Overall | Placebo | MRA | |||
| CV death or HF hospitalization | 0.27 | ||||
| ≤105 mm Hg | 312 (44.4) | 176 (48.5) | 136 (40.1) | 0.74 (0.59–0.94), 0.012 | |
| >105 to ≤115 mm Hg | 319 (36.7) | 177 (41.1) | 142 (32.2) | 0.71 (0.56–0.90), 0.004 | |
| >115 to ≤125 mm Hg | 293 (30.5) | 177 (35.8) | 116 (24.9) | 0.62 (0.49–0.79), <0.001 | |
| >125 to ≤135 mm Hg | 222 (27.0) | 129 (30.6) | 93 (23.2) | 0.71 (0.54–0.94), 0.015 | |
| >135 mm Hg | 275 (26.4) | 169 (33.6) | 106 (19.7) | 0.52 (0.40–0.67), <0.001 | |
| Overall | 1,421 (32.35) | 828 (37.4) | 593 (17.2) | 0.66 (0.59–0.73), <0.001 | |
| Heart failure hospitalization | 0.44 | ||||
| ≤105 mm Hg | 192 (27.4) | 113 (31.1) | 79 (23.3) | 0.66 (0.49–0.89), 0.006 | |
| >105 to ≤115 mm Hg | 227 (26.1) | 131 (30.4) | 96 (21.9) | 0.63 (0.48–0.83), 0.001 | |
| >115 to ≤125 mm Hg | 189 (19.7) | 110 (22.2) | 79 (17.0) | 0.69 (0.51–0.94), 0.017 | |
| >125 to ≤135 mm Hg | 139 (16.9) | 84 (19.9) | 55 (13.7) | 0.63 (0.44–0.90), 0.010 | |
| >135 mm Hg | 185 (17.8) | 115 (22.9) | 70 (13.0) | 0.50 (0.37–0.68), <0.001 | |
| Overall | 932 (21.2) | 553 (25.0) | 379 (17.4) | 0.63 (0.55–0.72), <0.001 | |
| Cardiovascular death | 0.84 | ||||
| ≤105 mm Hg | 216 (30.8) | 119 (32.8) | 97 (28.6) | 0.79 (0.59–1.04), 0.092 | |
| >105 to ≤115 mm Hg | 200 (23.0) | 110 (25.5) | 90 (20.5) | 0.82 (0.62–1.11), 0.197 | |
| >115 to ≤125 mm Hg | 178 (18.5) | 107 (21.6) | 71 (15.3) | 0.67 (0.49–0.91), 0.010 | |
| >125 to ≤135 mm Hg | 131 (15.9) | 76 (18.0) | 55 (13.7) | 0.72 (0.50–1.03), 0.076 | |
| >135 mm Hg | 145 (13.9) | 87 (17.3) | 58 (10.8) | 0.61 (0.44–0.86), 0.005 | |
| Overall | 870 (19.8) | 499 (22.5) | 371 (17.0) | 0.71 (0.62–0.82), <0.001 | |
| All-cause death | 0.95 | ||||
| ≤105 mm Hg | 253 (36.0) | 144 (39.7) | 109 (32.2) | 0.72 (0.56–0.94), 0.015 | |
| >105 to ≤115 mm Hg | 243 (27.9) | 135 (31.3) | 108 (24.6) | 0.78 (0.60–1.02), 0.073 | |
| >115 to ≤125 mm Hg | 214 (22.3) | 125 (25.3) | 89 (19.1) | 0.71 (0.53–0.94), 0.016 | |
| >125 to ≤135 mm Hg | 154 (18.7) | 86 (20.4) | 68 (17.0) | 0.79 (0.57–1.10), 0.163 | |
| >135 mm Hg | 188 (18.1) | 109 (21.7) | 79 (14.7) | 0.67 (0.50–0.90), 0.009 | |
| Overall | 1,052 (23.9) | 599 (27.1) | 453 (20.8) | 0.72 (0.64–0.82), <0.001 | |
Values are n (%), unless otherwise noted.
CI = confidence interval; CV = cardiovascular; HF = heart failure; HR = hazard ratio; MRA = mineralocorticoid receptor antagonist; SBP = systolic blood pressure.
∗
The p values indicate interactions between SBP categories and treatment effects.